Showing 3671-3680 of 5333 results for "".
- FDA Approves Rinvoq for Adults and Children 12 Years and Older with Refractory, Moderate to Severe ADhttps://practicaldermatology.com/news/us-fda-approves-rinvoq-for-adults-and-children-12-years-and-older-with-refractory-moderate-to-severe-ad/2461036/The FDA has given its nod to AbbVie’s Rinvoq (upadacitinib) for the treatment of moderate to severe atopic dermatitis in adults and children 12 years of age and older whose disease did not respond to previous treatment and is not well controlled with other pills or injections, including bio
- BTL Introduces EMFACE Technologyhttps://practicaldermatology.com/news/btl-introduces-emface-technology/2461033/Described as the result of many years of institutional knowledge of the simultaneous emission of radio frequency and electromagnetic energies, EMFACE™ is the newest innovation from BTL. It utilizes a patented technology of muscle contraction and skin tissue heating. &quo
- $511M SPAC Deal for Sunevahttps://practicaldermatology.com/news/511m-spac-deal-for-suneva/2461032/Suneva Medical, Inc. and Viveon Health Acquisition Corp., a special purpose acquisition company (SPAC), are joining forces to form a regenerative aesthetics company. Upon completion of the transaction, the combined company's securities are expected to be traded on the NYSE unde
- Vial Launches Dermatology CROhttps://practicaldermatology.com/news/vial-launches-dermatology-cro/2461031/Vial has launched the Vial Dermatology CRO, dubbing it “The CRO Built for Sponsors.” The San Francisco-based company will rely on a clinic network of more than 35 dermatology clinics across the country to re
- Cybersecurity Firm Offers Tips to Protect Dermatology Practice Datahttps://practicaldermatology.com/news/cybersecurity-firm-offers-tips-to-protect-dermatology-practice-data/2461029/Ransomware attacks continue to target the healthcare sector. Black Talon Security, a leading NY-based national cybersecurity firm, offers 10 tips that all dermatology practices should follow to keep data secure and protect patient r
- Galderma Completes Alastin Acquisitionhttps://practicaldermatology.com/news/galderma-completes-alastin-acquisition/2461026/Having received antitrust clearance from US authorities, Galderma has completed the acquisition of Alastin Skincare®, Inc., a specialty aesthetics company dedicated to developing innovative and clinically-tested physician-dispens
- Survey: Consumers Interested in Medical Cannabis Products for Inflammatory Skin Disordershttps://practicaldermatology.com/news/survey-consumers-interested-in-medical-cannabis-products-for-inflammatory-skin-disorders/2461025/Patients with dermatologic conditions are open to trying medical cannabis products (MCPs) as potential treatments, according to a new study from George Washington University (GW) School of Medicine and Health Sciences (SMHS) and University of Maryland researchers. “MCPs, which are
- First Patient Enrolled in Phase 2b Study of Oral Orismilast in Psoriasishttps://practicaldermatology.com/news/first-patient-enrolled-in-phase-2b-study-of-oral-orismilast-in-psoriasis/2461024/The first patient has been enrolled in IASOS, a Phase 2b dose-ranging study evaluating the safety and efficacy of oral orismilast in patients with moderate to severe psoriasis, according to UNION therapeutics. Orismilast is a next generation PDE4 inhibitor with broad anti-inflammatory p
- The American Skin Association Re-ups Support for the SPOTS Programhttps://practicaldermatology.com/news/the-american-skin-association-re-ups-support-for-the-spots-program/2461023/The American Skin Association (ASA) is renewing its support for the SPOTS (Sun Protection Outreach Teaching by Students) program. SPOTS is a public health outreach educational program aimed at both elementary school students and young teenagers. The comprehensive pr
- Dermatologist Tackles Misinformation Related to COVID-19 Vaccines and Injectable Fillers and Toxinxhttps://practicaldermatology.com/news/dermatologist-tackles-misinformation-related-to-covid-19-vaccines-and-injectable-fillers/2461022/With a recent article in the Wall Street Journal article suggesting that patients must choose between neurotoxin treatments or COVID-19 vaccines, dermatologists are scurrying to set the record straight. While there have been rare reports of non-life-threatening, transient reactions